SCHEMBL5429693

SCHEMBL5429693

CNC(=O)c1cc(Oc2cccc(C(=O)N(O)c3cccc(C)c3)c2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.48
BRAF P15056 7/20 0.47
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
RET P07949 2/20 0.44
PLK4 O00444 1/20 0.43
AURKA O14965 1/20 0.43
MAPK13 O15264 1/20 0.43
JAK2 O60674 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
LYN P07948 1/20 0.43
ROS1 P08922 1/20 0.43
SRC P12931 1/20 0.43
RPS6KB1 P23443 1/20 0.43
EPHA2 P29317 1/20 0.43
TYK2 P29597 1/20 0.43
AXL P30530 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5427748 0.92 BRAF (0.54) KDRBRAFHSD17B1HSD17B2RET
SCHEMBL5429868 0.88 KDR (0.47) KDRBRAFHSD17B1HSD17B2RET
SCHEMBL167783 0.83 KDR (0.58) KDRBRAFRETPLK4AURKA
SCHEMBL5421746 0.80 KDR (0.54) KDRBRAFRETPLK4AURKA
SCHEMBL3578600 0.79 BRAF (0.60) KDRBRAFRETPLK4AURKA
SCHEMBL5435587 0.79 KDR (0.54) KDRBRAFRETPLK4AURKA
SCHEMBL5423254 0.78 KDR (0.56) KDRBRAFRETPLK4AURKA
SCHEMBL12020936 0.76 KDR (0.55) KDRBRAFRETPLK4AURKA
SCHEMBL5429857 0.76 KMT2A (0.54) KDRBRAFRAF1
SCHEMBL5429683 0.76 KDR (0.55) KDRBRAFRETPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 US claimed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors TIE1, KDR, FLT1 KDR 2/4885BRAF 49/4885HSD17B1 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.